A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Recruiting

Phase 1

Phase 2

VP-001A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Sponsor:

PYC Therapeutics

Code:

NCT06852963

Conditions

Retinitis Pigmentosa 11

Retinal Degeneration

Retinal Disease

Eye Diseases Hereditary

Retinal Dystrophies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VP-001

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-03. This information was provided to ClinicalTrials.gov by PYC Therapeutics on 2025-12-02.